Interpace Diagnostics (Exotistan) Buy Hold or Sell Recommendation

PDII -- Exotistan Stock  

USD 0.53  0.53  9,223,372,036,855%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Interpace Diagnostics Group is 'Strong Sell'. Macroaxis provides Interpace Diagnostics buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding PDII positions. The advice algorithm takes into account all of Interpace Diagnostics available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from PDII buy-and-hold prospective. Additionally take a look at Interpace Diagnostics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus.

Time Horizon

Risk Tolerance

Symbol
Execute Advice
Sell Interpace DiagnosticsBuy Interpace Diagnostics
Not Rated
For the selected time horizon Interpace Diagnostics Group has a risk adjusted performance of 0.0, jensen alpha of 0.0, total risk alpha of 0.0, sortino ratio of 0.0 and treynor ratio of 0.0
We provide buy, hold, or sell suggestion to complement the regular expert consensus on Interpace Diagnostics. Our dynamic recommendation engine utilizes multi - dimensional algorithm to analyze the organization potential to grow using all technical and fundamental data available at the time. To make sure Interpace Diagnostics Group is not overpriced, please check out all Interpace Diagnostics fundamentals including its Net Income, Number of Employees, Z Score, as well as the relationship between Debt to Equity and Retained Earnings .

Interpace Diagnostics Greeks

α
Alpha over DOW
=0.00
β
Beta against DOW=0.00
σ
Overall volatility
=0.00
Ir
Information ratio =0.00

Interpace Diagnostics Volatility Alert

Interpace Diagnostics Group exhibits very low volatility with skewness of 0.0 and kurtosis of 0.0. However, we advise investors to further study Interpace Diagnostics Group technical indicators to make sure all market info is available and is reliable. Interpace Diagnostics Group is a potential penny stock. Although Interpace Diagnostics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial stock hype. Please make sure you totally understand upside potential and downside risk of investing in Interpace Diagnostics Group. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings,sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that has been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The one and only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
    
 Better Than Average     
    
 Worse Than Average Compare Interpace Diagnostics to competition

Interpace Diagnostics Fundamental Vs Peers

FundamentalsInterpace DiagnosticsPeer Average
Return On Asset(15.11) % (15.64) %
Profit Margin(16.56) % (5.50) %
Operating Margin(13.94) % (10.91) %
Current Valuation28.04 M152.14 B
Shares Outstanding16.74 M1.43 B
Shares Owned by Insiders61.46 % 6.91 %
Shares Owned by Institutions21.20 % 18.37 %
Number of Shares Shorted608.44 K3.24 M
Price to Earning748.00 times40.69 times
Price to Book1.66 times14.44 times
Price to Sales0.07 times17.81 times
Revenue140.12 M9.85 B
Gross Profit18.54 M21.75 B
Net Income(19.75 M)517.71 M
Cash and Equivalents9.4 M3.89 B
Cash per Share0.56 times5.17 times
Total Debt27.91 M7.36 B
Debt to Equity4.76 % 0.72 %
Current Ratio1.02 times3.30 times
Cash Flow from Operations(21.95 M)1.25 B
Earnings Per Share1.53 times2.30 times
Number of Employees77510.67 K
Beta-0.050.34
Market Capitalization9.54 M29.78 B
Total Asset99.29 M126.86 B
Retained Earnings(115.64 M)38.24 B
Working Capital573 K3.58 B
Current Asset32.1 M36.8 B
Current Liabilities31.53 M33.34 B
Z Score-0.4708.73

Interpace Diagnostics Alerts

Trading Alerts and Improvement Suggestions
Interpace Diagnostics generates negative expected return over the last 30 days
Interpace Diagnostics has some characteristics of a very speculative penny stock
Interpace Diagnostics has high likelihood to experience some financial distress in the next 2 years
The company reported previous year revenue of 140.12 M. Net Loss for the year was (19.75 M) with profit before overhead, payroll, taxes, and interest of 18.54 M.
PDI INC currently holds about 9.4 M in cash with (21.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.56 which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 61.0% of the company outstanding shares are owned by corporate insiders
Latest headline from stanleybusinessdaily.com: Interpace Diagnostics Group, Inc. Has Reported Sales Growth of 0.27485 Year Over Year
Additionally take a look at Interpace Diagnostics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus. Please also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of macroaxis ideas.